Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av testikkelkreft
  • Engelsk tittel -
  • Versjon - 3
  • Status - Publisert
  • IS-nr - 2365
  • ISBN - 978-82-8081-408-1
  • DOI -
  • Revisjonsdato - 03.09.2015
  • Neste revisjon -
  • Publikasjonsdato - 06.12.2011
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Torgrim Tandstad et al
  • Publikasjonstype - Nasjonale retningslinjer
  1. Cancer Registry of Norway. Cancer in Norway 2010 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo.: Cancer Registry of Norway.; 2012.
  2. Richiardi L, Bellocco R, Adami HO, Torrang A, Barlow L, Hakulinen T, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2157-66.
  3. Heimdal K, Olsson H, Tretli S, Fossa SD, Borresen AL, Bishop DT. A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer. 1997;75(7):1084-7.
  4. Looijenga LH. Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights. The Journal of pathology. 2009;218(2):146-62.
  5. Wohlfahrt-Veje C, Main KM, Skakkebaek NE. Testicular dysgenesis syndrome: foetal origin of adult reproductive problems. Clin Endocrinol (Oxf). 2009;71(4):459-65.
  6. Moger TA, Aalen OO, Heimdal K, Gjessing HK. Analysis of testicular cancer data using a frailty model with familial dependence. Stat Med. 2004;23(4):617-32.
  7. Mai PL, Friedlander M, Tucker K, Phillips KA, Hogg D, Jewett MA, et al. The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol. 2010;28(5):492-9.
  8. de Jong J, Stoop H, Gillis AJ, van Gurp RJ, van de Geijn GJ, Boer M, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. The Journal of pathology. 2008;215(1):21-30.
  9. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97(21):1580-8.
  10. Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol. 2007;46(4):480-9.
  11. Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol. 2007;52(5):1438-47.
  12. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25(6):708-14.
  13. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70.
  14. Oldenburg J, Fossa SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics. 2008;9(10):1521-30.
  15. Brydoy M, Storstein A, Dahl O. Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiother Oncol. 2007;82(2):137-44.
  16. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682-95.
  17. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18(2):241-8.
  18. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv. 2008;2(3):128-37.
  19. Wethal T, Kjekshus J, Roislien J, Ueland T, Andreassen AK, Wergeland R, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv. 2007;1(1):8-16.
  20. Haugnes HS, Aass N, Fossa SD, Dahl O, Brydoy M, Aasebo U, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol. 2009;27(17):2779-86.
  21. Orre IJ, Fossa SD, Murison R, Bremnes R, Dahl O, Klepp O, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res. 2008;64(4):363-71.
  22. Skaali T, Fossa SD, Bremnes R, Dahl O, Haaland CF, Hauge ER, et al. Fear of recurrence in long-term testicular cancer survivors. Psychooncology. 2009;18(6):580-8.
  23. Grov EK, Fossa SD, Bremnes RM, Dahl O, Klepp O, Wist E, et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol. 2009;48(6):842-9.
  24. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-65.
  25. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533-44.
  26. Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102(16):1253-62.
  27. Schairer C, Hisada M, Chen BE, Brown LM, Howard R, Fossa SD, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst. 2007;99(16):1248-56.
  28. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340-8.
  29. Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Stahl E, et al. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol. 2012;51(2):168-76.
  30. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(13):2122-8.
  31. Oldenburg J, Wahlqvist R, Fossa SD. Late relapse of germ cell tumors. World J Urol. 2009;27(4):493-500.
  32. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Annals of Oncology. 2008;19(2):259-64.
  33. Nichols CR, Kollmannsberger C. Vox populi: Using community-based studies to determine best management of early-stage nonseminoma. J Clin Oncol. 2009;27(13):2114-6.
  34. Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Stahl O, Klepp O, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 2011;29(15):2032-9.
  35. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478-96.
  36. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497-513.
  37. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncology. 2013;24(4):878-88.
  38. Eble JN, Sauter G, Epstein JI, I.A. S. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon 2005. 2004.
  39. Peckham MJ, Barrett A, Mcelwain TJ, Hendry WF. Combined Management of Malignant Teratoma of the Testis. Lancet. 1979;2(8137):267-70.
  40. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603.
  41. Sobin L, Gospodarowicz M, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell. 2010.
  42. Pinczowski D, Mclaughlin JK, Lackgren G, Adami HO, Persson I. Occurrence of Testicular Cancer in Patients Operated on for Cryptorchidism and Inguinal-Hernia. J Urology. 1991;146(5):1291-4.
  43. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. Brit Med J. 2000;321(7264):789-92.
  44. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urology. 2005;174(5):1819-22.
  45. Westergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. International Journal of Cancer. 1996;66(5):627-31.
  46. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer - An analysis of two patient populations and a review of the literature. Cancer. 1997;80(10):1954-60.
  47. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol. 2002;42(6):553-62; discussion 62-3.
  48. Wein AJ, Kavoussi LR, Campbell MF. Campbell-Walsh urology / editor-in-chief, Alan J. Wein ; [editors, Louis R. Kavoussi ... et al.]. 10th ed. Philadelphia, PA: Elsevier Saunders; 2012.
  49. Skakkebaek N. Possible Carcinoma-in-Situ of Testis. Lancet. 1972;2(7776):516-&.
  50. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The Epidemiology of Testicular Cancer in Young-Adults. Am J Epidemiol. 1980;112(2):232-46.
  51. Wanderas EH, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway 1955-1992. European Journal of Cancer. 1995;31A(12):2044-8.
  52. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, et al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer. 2001;91(7):1394-401.
  53. Hartmann JT, Fossa SD, Nichols CR, Droz JP, Horwich A, Gerl A, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst. 2001;93(22):1733-8.
  54. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Annals of Oncology. 2002;13(7):1017-28.
  55. Richie JP, Birnholz J, Garnick MB. Ultrasonography as a Diagnostic Adjunct for the Evaluation of Masses in the Scrotum. Surg Gynecol Obstet. 1982;154(5):695-8.
  56. Nichols C. Testicular cancer. Curr Prob Cancer. 1998;22(4):187-+.
  57. Doherty FJ. Ultrasound of the Nonacute Scrotum. Semin Ultrasound Ct. 1991;12(2):131-56.
  58. Friedrich M, Claussen CD, Felix R. Immersion Ultrasound of Testicular Pathology. Radiology. 1981;141(1):235-7.
  59. Glazer HS, Lee JKT, Melson GL, Mcclennan BL. Sonographic Detection of Occult Testicular Neoplasms. American Journal of Roentgenology. 1982;138(4):673-5.
  60. Bockrath JM, Schaeffer AJ, Kies MS, Neiman HL. Ultrasound Identification of Impalpable Testicle Tumor. J Urology. 1983;130(2):355-6.
  61. Shawker TH, Javadpour N, Oleary T, Shapiro E, Krudy AG. Ultrasonographic Detection of Burned-out Primary Testicular Germ-Cell Tumors in Clinically Normal Testes. J Ultras Med. 1983;2(10):477-9.
  62. Jaganathan K, Ahmed S, Henderson A, Rane A. Current management strategies for testicular microlithiasis. Nature Clinical Practice Urology. 2007;4(9):492-7.
  63. White PM, Howard GCW, Best JJK, Wright AR. The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clinical Radiology. 1997;52(2):124-9.
  64. Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP. Identification of clinical stage a nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. Journal of Clinical Oncology. 1998;16(1):261-8.
  65. White PM, Adamson DJA, Howard GCW, Wright AR. Imaging of the thorax in the management of germ cell testicular tumours. Clinical Radiology. 1999;54(4):207-11.
  66. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Sleijfer DT, Schraffordt Koops H. Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumours of the testis. Eur J Surg Oncol. 1993;19(5):429-37.
  67. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, et al. Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience. Radiology. 1998;207(3):799-808.
  68. Klein EA. Tumor-Markers in Testis Cancer. Urologic Clinics of North America. 1993;20(1):67-73.
  69. Javadpour N. The Role of Biologic Tumor-Markers in Testicular Cancer. Cancer. 1980;45(7):1755-61.
  70. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkeaek NE, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol. 2002;20(6):1537-43.
  71. Petersen PM, Giwercman A, Skakkebaek NE, Rorth M. Gonadal function in men with testicular cancer. Seminars in Oncology. 1998;25(2):224-34.
  72. DeSantis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. International Journal of Cancer. 1999;83(6):864-5.
  73. Jacobsen KD, Fossa SD, Bjoro TP, Aass N, Heilo A, Stenwig AE. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. European Urology. 2002;42(3):229-37.
  74. Kliesch S, Behre HM, Jurgens H, Nieschlag E. Cryopreservation of semen from adolescent patients with malignancies. Medical and Pediatric Oncology. 1996;26(1):20-7.
  75. Giwercman A, Vondermaase H, Rorth M, Skakkebaek NE. Semen Quality in Testicular-Tumor and Cis in the Contralateral Testis. Lancet. 1993;341(8841):384-5.
  76. Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Human Reproduction. 1997;12(12):2830-5.
  77. Spermon JR, Kiemeney LALM, Meuleman EJH, Ramos L, Wetzels AMM, Witjes JA. Fertility in men with testicular germ cell tumors. Fertil Steril. 2003;79:1543-9.
  78. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A Review of Scrotal Violation in Testicular Cancer - Is Adjuvant Local Therapy Necessary. J Urology. 1995;153(3):981-5.
  79. Harding M, Paul J, Kaye SB. Does Delayed Diagnosis or Scrotal Incision Affect Outcome for Men with Nonseminomatous Germ-Cell Tumors. Brit J Urol. 1995;76(4):491-4.
  80. Leibovitch I, Baniel J, Foster RS, Donohue JP. The Clinical Implications of Procedural Deviations during Orchiectomy for Nonseminomatous Testis Cancer. J Urology. 1995;154(3):935-9.
  81. Robertson GSM. Radical Orchiectomy and Benign Testicular Conditions. Brit J Surg. 1995;82(3):342-5.
  82. Elert A, Olbert P, Hegele A, Barth P, Hofmann R, Heidenreich A. Accuracy of frozen section examination of testicular tumors of uncertain origin. European Urology. 2002;41(3):290-3.
  83. Leroy X, Rigot JM, Aubert S, Ballereau C, Gosselin B. Value of frozen section examination for the management of nonpalpable incidental testicular tumors. European Urology. 2003;44(4):458-60.
  84. Skoogh J, Steineck G, Cavallin-Stahl E, Wilderang U, Hakansson UK, Johansson B, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. International Journal of Andrology. 2011;34(2):183-92.
  85. Giannarini G, Dieckmann KP, Albers P, Heidenreich A, Pizzocaro G. Organ-Sparing Surgery for Adult Testicular Tumours: A Systematic Review of the Literature. European Urology. 2010;57(5):780-90.
  86. Heidenreich A, Weissbach L, Holtl W, Albers P, Kliesch S, Kohrmann KU, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urology. 2001;166(6):2161-5.
  87. Heidenreich A, Holtl W, Albrecht W, Pont T, Engelmann UH. Testis-preserving surgery in bilateral testicular germ cell tumours. Brit J Urol. 1997;79(2):253-7.
  88. Weissbach L. Organ-Preserving Surgery of Malignant Germ-Cell Tumors. J Urology. 1995;153(1):90-3.
  89. von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed). 1986;293(6559):1398-401.
  90. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol. 1998;160(4):1353-7.
  91. Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra JA, Borras J, et al. Incidence of contralateral germ cell testicular tumors in South Europe: Report of the experience at 2 Spanish university hospitals and review of the literature. J Urology. 2004;171(1):164-7.
  92. Herr HW, Sheinfeld J. Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urology. 1997;158(4):1331-4.
  93. Albers P, Goll A, Bierhoff E, Schoeneich G, Muller SC. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology. 1999;54(4):714-8.
  94. Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol. 1996;14(12):3126-32.
  95. Heidenreich A. Contralateral testicular biopsy in testis cancer: current concepts and controversies. Bju International. 2009;104(9B):1346-50.
  96. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51(1):175-83; discussion 83-5.
  97. Kliesch S, Thomaidis T, Schutte B, Puhse G, Kater B, Roth S, et al. Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS. 2003;111(1):70-4; discussion 5.
  98. Fossa SD, Aass N, Heilo A, Daugaard G, N ES, Stenwig AE, et al. Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol. 2003;14(9):1412-8.
  99. Dieckmann KP, Besserer A, Loy V. Low-Dose Radiation-Therapy for Testicular Intraepithelial Neoplasia. J Cancer Res Clin. 1993;119(6):355-9.
  100. Christensen TB, Daugaard G, Geertsen PE, von der Maase H. Effect of chemotherapy on carcinoma in situ of the testis. Annals of Oncology. 1998;9(6):657-60.
  101. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Brit J Cancer. 2003;88(6):828-31.
  102. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am. 1998;25(3):435-49.
  103. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007;64(3):182-97.
  104. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448-52.
  105. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29(6):719-25.
  106. Warde P, Jewett MA. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am. 1998;25(3):425-33.
  107. Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003;14(6):867-72.
  108. van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer. 2008;98(12):1894-902.
  109. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, et al. Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957-62.
  110. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146.
  111. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200-8.
  112. Melchior D, Hammer P, Fimmers R, Schuller H, Albers P. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res. 2001;21(4B):2989-93.
  113. Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue JP. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. Clin Oncol (R Coll Radiol). 2001;13(4):296-300.
  114. Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys. 1989;16(2):383-8.
  115. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol. 1993;11(3):415-24.
  116. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429-39.
  117. Horwich A, Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol. 1994;30(3):193-8.
  118. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-84.
  119. Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol. 1997;31(4):355-9.
  120. Chung PW, Daugaard G, Tyldesley S, Panzarella T, Kollmannsberger CK, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol. 2010;28(7s):suppl; abstr 4535.
  121. Aparicio J, Maroto P, del Muro XG, Guma J, Sanchez-Munoz A, Margeli M, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35):4677-81.
  122. Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2(8554):294-8.
  123. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10(11):1762-8.
  124. Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int. 1999;83(1):76-82.
  125. Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology. 2004;63(3):556-61.
  126. Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, et al. Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience. Eur Urol. 2010.
  127. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003;111(1):76-83; discussion -5.
  128. Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21(6):1296-301.
  129. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14(4):1106-13.
  130. Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol. 1992;148(5):1453-5; discussion 5-6.
  131. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol. 1993;23(4):444-9.
  132. Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol. 1999;161(4):1148-52.
  133. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol. 1996;14(2):441-8.
  134. Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol. 2004;46(2):209-14; discussion 14-5.
  135. Maroto P, Garcia del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol. 2005;16(12):1915-20.
  136. Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol. 2001;165(2):441-4.
  137. Albers P, Siener R, Krege S, Schmelz H-U, Dieckmann K-P, Heidenreich A, et al. Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008:JCO.2007.12.0899.
  138. Tandstad T, Cavallin-Stahl E, Dahl O, Haugnes HS, Langberg CW, Laurell A, et al. One course of adjuvant BEP in clinical stage I, nonseminoma: Mature and expanded results from the SWENOTECA group. ASCO Meeting Abstracts. 2013;31(15_suppl):4553.
  139. Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel Huinink WW, van de Vijver M, et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology. 2002;59(6):923-9.
  140. Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int. 2000;86(1):89-93.
  141. Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol. 1990;1(4):281-8.
  142. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505-12.
  143. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 1990;8(3):509-18.
  144. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol. 1985;134(3):485-9.
  145. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237-43.
  146. Lashley DB, Lowe BA. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am. 1998;25(3):405-23.
  147. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer. 1995;31A(10):1599-604.
  148. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol. 1991;9(8):1393-6.
  149. Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol. 1984;131(4):677-80.
  150. Foster RS, Roth BJ. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol. 1998;25(2):145-53.
  151. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435-40.
  152. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. JClinOncol. 2011;29(6):719-25.
  153. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in testicular cancer survivors: A 20 year follow-up study. Journal of Clinical Oncology. 2010;28(30):4649-57.
  154. Garcia-del-Muro X, Maroto P, Guma J, Sastre J, Lopez Brea M, Arranz JA, et al. Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study. Journal of Clinical Oncology. 2008;26(33):5416-21.
  155. Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, et al. Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. Journal of Clinical Oncology. 2005;23(36):9290-4.
  156. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. RadiotherOncol. 2001;59(1):5-11.
  157. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. JClinOncol. 2003;21(6):1101-6.
  158. Chung PW, Gospodarowicz MK, Panzarella T, Jewett MA, Sturgeon JF, Tew-George B, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. EurUrol. 2004;45(6):754-9.
  159. Swedish, Norwegian Testicular Cancer Project S. Swenoteca VII. A revised continuation of Swenoteca V. Testicular seminoma. 2007.
  160. von der MH. Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? RadiotherOncol. 2001;59(1):1-3.
  161. Domont J, Massard C, Patrikidou A, Bossi A, de Crevoisier R, Rose M, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urologic oncology. 2011.
  162. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU Guidelines on Testicular Cancer: 2011 Update. European Urology. 2011;60(2):304-19.
  163. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncology. 2012.
  164. de WR, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. JClinOncol. 1997;15(5):1837-43.
  165. Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. BrJ Cancer. 2000;83(12):1623-9.
  166. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. BrJCancer. 2004;91(4):683-7.
  167. Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, et al. Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta oncologica. 2012.
  168. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. JUrol. 2002;168(5):1975-9.
  169. Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. UrolInt. 1996;57(1):38-42.
  170. Kamat MR, Kulkarni JN, Tongaonkar HB, Ravi R. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. JSurgOncol. 1992;51(1):65-7.
  171. Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Stahl O, Klepp O, et al. Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group. JClinOncol. 2011;29(15):2032-9.
  172. Swenoteca Working G. SWENOTECA VIII: A revised continuation of SWENOTECA IV and VI. A cancer care program. Non-seminomatous germ cell tumours (NSGCT). 2012.
  173. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. Journal of Clinical Oncology. 1997;15(2):594-603.
  174. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol. 2008;53(3):497-513.
  175. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. NEnglJMed. 1987;316(23):1435-40.
  176. de WR, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. JClinOncol. 2001;19(6):1629-40.
  177. Dahl O, Lehne G, Baksaas I, Kval›y S, Christoffersen T. Cytostatikaboken, medikamentell kreftbehandling2009.
  178. Bokemeyer C, Kuczyk MA, Kohne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. AnnHematol. 1996;72(1):1-9.
  179. Fossa SD, Kaye SB, Mead GM, Cullen M, de WR, Bodrogi I, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. JClinOncol. 1998;16(2):716-24.
  180. Sleijfer S. Bleomycin-Induced Pneumonitis. Chest. 2001;120(2):617-24.
  181. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. AnnOncol. 2003;14(1):91-6.
  182. Goldiner PL, Carlon GC, Cvitkovic E, Schweizer O, Howland WS. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. BrMedJ. 1978;1(6128):1664-7.
  183. Douglas MJ, Coppin CM. Bleomycin and subsequent anaesthesia: a retrospective study at Vancouver General Hospital. CanAnaesthSocJ. 1980;27(5):449-52.
  184. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? JUrol. 1998;160(4):1347-52.
  185. de Wit R, Sleijfer S, Kaye SB, Horwich A, Mead B, Sleijfer DT, et al. Bleomycin and scuba diving: where is the harm? The Lancet Oncology. 2007;8(11):954-5.
  186. Haugnes HS, Aass N, Fossa SD, Dahl O, Brydoy M, Aasebo U, et al. Pulmonary Function in Long-Term Survivors of Testicular Cancer. JClinOncol. 2009;27(17):2779-86.
  187. Weiss B. Hypersensitivity reactions.  The chemotherapy source book: Baltimore, Williams and Wilkins; 1996. p. 613-34.
  188. Siderov J, Prasad P, De BR, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. BrJCancer. 2002;86(1):12-3.
  189. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. JClinOncol. 2000;18(10):2169-78.
  190. Shim K, Potvin KR, Mills K, Whiston F, Stitt L, Winquist E. Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy. J Clin Oncol. 2009;27:(suppl; abstr e16109).
  191. Culine S, Kerbrat P, Kramar A, Theodore C, Chevreau C, Geoffrois L, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). AnnOncol. 2007;18(5):917-24.
  192. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. Journal of Clinical Oncology. 1997;15(5):1844-52.
  193. de WR, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de PL, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. BrJCancer. 1998;78(6):828-32.
  194. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. JClinOncol. 1998;16(4):1287-93.
  195. Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, Peny J, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. EurUrol. 2007;51(3):739-46.
  196. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. JClinOncol. 2001;19(9):2534-41.
  197. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. JClinOncol. 2004;22(19):3868-76.
  198. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. JClinOncol. 1991;9(7):1163-72.
  199. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David CE, Vogelzang N, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer. 2003;97(8):1869-75.
  200. de WR, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. BrJCancer. 1995;71(6):1311-4.
  201. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. JClinOncol. 2007;25(3):247-56.
  202. Daugaard G, Skoneczna I, Aass N, de WR, De SM, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). AnnOncol. 2011;22(5):1054-61.
  203. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical Treatment of Advanced Testicular Cancer. Jama. 2008;299(6):672-84.
  204. Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. Journal of Clinical Oncology. 1998;16(2):692-701.
  205. Ondrus D, Hornak M, Breza J, Mat'oska J, Schnorrer M, Belan V, et al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. IntUrolNephrol. 2001;32(4):665-7.
  206. Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. EurJCancer. 1993;29A(7):961-5.
  207. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer. 1994;73(10):2520-6.
  208. Andre F, Fizazi K, Culine S, Droz J, Taupin P, Lhomme C, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. EurJCancer. 2000;36(11):1389-94.
  209. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. JUrol. 1989;141(3):557-9.
  210. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. JClinOncol. 1990;8(10):1683-94.
  211. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. EurJCancer. 1997;33(6):843-7.
  212. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 1998;83(7):1409-19.
  213. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94(6):1668-76.
  214. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. SeminUrolOncol. 2002;20(4):262-71.
  215. Foster RS, Donohue JP. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? UrolClinNorth Am. 1998;25(3):479-84.
  216. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. IntJCancer. 1999;83(6):856-9.
  217. Vergouwe Y, Steyerberg EW, de WR, Roberts JT, Keizer HJ, Collette L, et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. BrJCancer. 2003;88(6):843-7.
  218. Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, et al. Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery. Journal of Clinical Oncology. 2010;28(4):537-42.
  219. Ehrlich Y, Brames MJ, Beck SDW, Foster RS, Einhorn LH. Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients With Disseminated Nonseminomatous Germ Cell Tumors: Is a Postchemotherapy Retroperitoneal Lymph Node Dissection Needed After Complete Remission? J Clin Oncol. 2010;28(4):531-6.
  220. Jacobsen KD, Ous S, Waehre H, Trasti H, Stenwig AE, Lien HH, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. BrJCancer. 1999;80(1-2):249-55.
  221. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. JClinOncol. 2007;25(9):1033-7.
  222. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses. J Clin Oncol. 2003;21(17):3310-7.
  223. Kuczyk M, Machtens S, Stief C, Jonas U. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). IntJCancer. 1999;83(6):852-5.
  224. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994;74(4):1329-34.
  225. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? BrJUrol. 1997;80(4):653-7.
  226. Hendry WF, A'Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. BrJUrol. 1993;71(2):208-13.
  227. Wood DP, Jr., Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. JUrol. 1992;148(6):1812-5.
  228. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. JUrol. 1995;153(3 Pt 2):976-80.
  229. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. AnnOncol. 1997;8(6):531-8.
  230. Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? BrJUrol. 1998;81(2):295-300.
  231. Tekgul S, Ozen HA, Celebi I, Ozgu I, Ergen A, Demircin M, et al. Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. Urology. 1994;43(3):349-54.
  232. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. JClinOncol. 2001;19(10):2647-57.
  233. de Bruin MJ, Oosterhof GO, Debruyne FM. Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. BrJUrol. 1993;71(3):336-9.
  234. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. JClinOncol. 2005;23(12):2781-8.
  235. Besse B, Grunenwald D, Flechon A, Caty A, Chevreau C, Culine S, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. JThoracCardiovascSurg. 2009;137(2):448-52.
  236. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors. The New England Journal of Medicine. 2007;357(4):340-8.
  237. Salvati M, Piccirilli M, Raco A, Santoro A, Frati R, Lenzi J, et al. Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurgical review. 2006;29(2):130-7.
  238. Nonomura N, Nagahara A, Oka D, Mukai M, Nakai Y, Nakayama M, et al. Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol. 2009;16(11):887-93.
  239. Forquer JA, Harkenrider M, Fakiris AJ, Timmerman RD, Cavaliere R, Henderson MA, et al. Brain metastasis from non-seminomatous germ cell tumor of the testis. Expert review of anticancer therapy. 2007;7(11):1567-80.
  240. Doyle DM, Einhorn LH. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys. 2008;70(5):1361-4.
  241. Menendez JY, Bauer DF, Shannon CN, Fiveash J, Markert JM. Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. Journal of neuro-oncology. 2012;109(3):513-9.
  242. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008;26(34):5524-9.
  243. Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, et al. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol. 2010;21(9):1858-63.
  244. Olofsson SE, Dahl O, Jerkeman G, Cohn-Cedermark G, Klepp OH, Stierner U, et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol. 2009;27(15s):suppl; abstr 5015.
  245. Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28(33):4906-11.
  246. Lorch A, Mollevi A, Kramar A, Einhorn LH, Necchi C. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol. 2010;28(15s):(suppl: abstr 4513).
  247. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549-55.
  248. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559-63.
  249. De Giorgi U, Rosti G, Aieta M, Testore F, Burattini L, Fornarini G, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol. 2006;50(5):1032-8; discussion 8-9.
  250. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22(1):108-14.
  251. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25(5):513-6.
  252. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19(3):448-53.
  253. De Giorgi U, Rosti G, Papiani G, Aieta M, Fochessati F, Paoluzzi L, et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol. 2004;27(5):457-60.
  254. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol. 2004;46(2):216-21.
  255. Nicolai N, Necchi A, Gianni L, Piva L, Biasoni D, Torelli T, et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int. 2009;104(3):340-6.
  256. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843-7.
  257. Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schoffski P, et al. Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Annals of surgery. 2005;242(2):260-6.
  258. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol. 2001;19(10):2647-57.
  259. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164(2):381-4.
  260. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006;107(7):1483-90.
  261. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11(7):1294-9.
  262. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer. 1999;80(9):1392-9.
  263. Foster RS, Donohue JP. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am. 1998;25(3):479-84.
  264. Wood DP, Jr., Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol. 1992;148(6):1812-5; discussion 5-6.
  265. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8(1):41-7.
  266. Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER, Jr., Einhorn LH, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology. 1997;50(6):957-62.
  267. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 1994;43(1):74-80.
  268. Kisbenedek L, Bodrogi I, Szeldeli P, Baki M, Tenke P, Horti J. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy. Int Urol Nephrol. 1995;27(3):325-9.
  269. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11(2):324-9.
  270. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol. 1998;81(6):884-8.
  271. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol. 1997;8(6):531-8.
  272. Oldenburg J, Martin JM, Fossa SD. Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis. J Clin Oncol. 2006;24(35):5503-11.
  273. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299(6):672-84.
  274. Schmoll HJ. Extragonadal germ cell tumors. Ann Oncol. 2002;13 Suppl 4:265-72.
  275. Utz DC, Buscemi MF. Extragonadal testicular tumors. The Journal of urology. 1971;105(2):271-4.
  276. Ueno T, Tanaka YO, Nagata M, Tsunoda H, Anno I, Ishikawa S, et al. Spectrum of germ cell tumors: from head to toe. Radiographics. 2004;24(2):387-404.
  277. Bussey KJ, Lawce HJ, Olson SB, Arthur DC, Kalousek DK, Krailo M, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences--a Children's Cancer Group study. Genes, chromosomes & cancer. 1999;25(2):134-46.
  278. Marina N, London WB, Frazier AL, Lauer S, Rescorla F, Cushing B, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol. 2006;24(16):2544-8.
  279. Scotting PJ. Are cranial germ cell tumours really tumours of germ cells? Neuropathology and applied neurobiology. 2006;32(6):569-74.
  280. Schneider DT, Schuster AE, Fritsch MK, Hu J, Olson T, Lauer S, et al. Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer research. 2001;61(19):7268-76.
  281. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 2002;20(7):1864-73.
  282. Scholz M, Zehender M, Thalmann GN, Borner M, Thoni H, Studer UE. Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol. 2002;13(1):121-4.
  283. De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World journal of urology. 2004;22(1):41-6.
  284. Rogers SJ, Mosleh-Shirazi MA, Saran FH. Radiotherapy of localised intracranial germinoma: time to sever historical ties? The lancet oncology. 2005;6(7):509-19.
  285. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. The Journal of urology. 2002;168(5):1975-9.
  286. Vuky J, Bains M, Bacik J, Higgins G, Bajorin DF, Mazumdar M, et al. Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol. 2001;19(3):682-8.
  287. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754-65.
  288. Kumano M, Miyake H, Hara I, Furukawa J, Takenaka A, Fujisawa M. First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors. Int J Urol. 2007;14(4):336-8.
  289. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, et al., editors. Guidelines on testicular cancer2008: European Association of Urology.
  290. Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. The American journal of surgical pathology. 1998;22(11):1361-7.
  291. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. The American journal of surgical pathology. 1985;9(3):177-92.
  292. Young RH, Koelliker DD, Scully RE. Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases. The American journal of surgical pathology. 1998;22(6):709-21.
  293. Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. American journal of clinical pathology. 1980;74(5):607-19.
  294. Zukerberg LR, Young RH, Scully RE. Sclerosing Sertoli cell tumor of the testis. A report of 10 cases. The American journal of surgical pathology. 1991;15(9):829-34.
  295. Emerson RE, Ulbright TM. Morphological approach to tumours of the testis and paratestis. Journal of clinical pathology. 2007;60(8):866-80.
  296. McCluggage WG, Shanks JH, Arthur K, Banerjee SS. Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology. 1998;33(4):361-8.
  297. Mineur P, De Cooman S, Hustin J, Verhoeven G, De Hertogh R. Feminizing testicular Leydig cell tumor: hormonal profile before and after unilateral orchidectomy. J Clin Endocrinol Metab. 1987;64(4):686-91.
  298. Bercovici JP, Nahoul K, Tater D, Charles JF, Scholler R. Hormonal profile of Leydig cell tumors with gynecomastia. J Clin Endocrinol Metab. 1984;59(4):625-30.
  299. Haas GP, Pittaluga S, Gomella L, Travis WD, Sherins RJ, Doppman JL, et al. Clinically occult Leydig cell tumor presenting with gynecomastia. The Journal of urology. 1989;142(5):1325-7.
  300. Rutgers JL, Young RH, Scully RE. The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. The American journal of surgical pathology. 1988;12(7):503-13.
  301. Maizlin ZV, Belenky A, Kunichezky M, Sandbank J, Strauss S. Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. J Ultrasound Med. 2004;23(7):959-64.
  302. Di Tonno F, Tavolini IM, Belmonte P, Bertoldin R, Cossaro E, Curti P, et al. Lessons from 52 patients with leydig cell tumor of the testis: the GUONE (North-Eastern Uro-Oncological Group, Italy) experience. Urologia internationalis. 2009;82(2):152-7.
  303. Mosharafa AA, Foster RS, Bihrle R, Koch MO, Ulbright TM, Einhorn LH, et al. Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer. 2003;98(4):753-7.
  304. Giglio M, Medica M, De Rose AF, Germinale F, Ravetti JL, Carmignani G. Testicular sertoli cell tumours and relative sub-types. Analysis of clinical and prognostic features. Urologia internationalis. 2003;70(3):205-10.
  305. Kratzer SS, Ulbright TM, Talerman A, Srigley JR, Roth LM, Wahle GR, et al. Large cell calcifying Sertoli cell tumor of the testis: contrasting features of six malignant and six benign tumors and a review of the literature. The American journal of surgical pathology. 1997;21(11):1271-80.
  306. Henley JD, Young RH, Ulbright TM. Malignant Sertoli cell tumors of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma. The American journal of surgical pathology. 2002;26(5):541-50.
  307. Plata C, Algaba F, Andujar M, Nistal M, Stocks P, Martinez JL, et al. Large cell calcifying Sertoli cell tumour of the testis. Histopathology. 1995;26(3):255-9.
  308. Anderson GA. Sclerosing Sertoli cell tumor of the testis: a distinct histological subtype. The Journal of urology. 1995;154(5):1756-8.
  309. Gabrilove JL, Freiberg EK, Leiter E, Nicolis GL. Feminizing and non-feminizing Sertoli cell tumors. The Journal of urology. 1980;124(6):757-67.
  310. Washecka R, Dresner MI, Honda SA. Testicular tumors in Carney's complex. The Journal of urology. 2002;167(3):1299-302.
  311. Young S, Gooneratne S, Straus FH, 2nd, Zeller WP, Bulun SE, Rosenthal IM. Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome. The American journal of surgical pathology. 1995;19(1):50-8.
  312. Kaplan GW, Cromie WJ, Kelalis PP, Silber I, Tank ES, Jr. Gonadal stromal tumors: a report of the Prepubertal Testicular Tumor Registry. The Journal of urology. 1986;136(1 Pt 2):300-2.
  313. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer. 1970;25(6):1340-56.
  314. Ulbright TM, Srigley JR, Reuter VE, Wojno K, Roth LM, Young RH. Sex cord-stromal tumors of the testis with entrapped germ cells: a lesion mimicking unclassified mixed germ cell sex cord-stromal tumors. The American journal of surgical pathology. 2000;24(4):535-42.
  315. Perito PE, Ciancio G, Civantos F, Politano VA. Sertoli-Leydig cell testicular tumor: case report and review of sex cord/gonadal stromal tumor histogenesis. The Journal of urology. 1992;148(3):883-5.
  316. Wegner HE, Dieckmann KP, Herbst H, Andresen R, Miller K. Leydig cell tumor--comparison of results of radical and testis-sparing surgery in a single center. Urologia internationalis. 1997;59(3):170-3.
  317. Gietema JA, Meinardi MT, Sleijfer DT, Hoekstra HJ, van der Graaf WT. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol. 2002;13(10):1616-20.
  318. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol. 2008;81(965):362-78.
  319. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97(14):1056-66.
  320. Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol. 1995;13(5):1188-94.
  321. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;25(11):1310-5.
  322. Cullen M. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Ann Oncol. 2012;23 Suppl 10:x342-8.
  323. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol. 1991;145(6):1178-83; discussion 82-3.
  324. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol. 1993;71(3):326-35.
  325. Allhoff EP, Liedke S, de Riese W, Stief C, Schneider B. Stage I seminoma of the testis. Adjuvant radiotherapy or surveillance? Br J Urol. 1991;68(2):190-4.
  326. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. JNCI Journal of the National Cancer Institute. 2005;97(14):1056-66.
  327. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. JClinOncol. 2012;30(30):3752-63.
  328. Howard R, Gilbert E, Lynch CF, Hall P, Storm H, Holowaty E, et al. Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients. Ann Epidemiol. 2008;18(5):416-21.
  329. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. JNCI Journal of the National Cancer Institute. 2005;97(18):1354-65.
  330. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. BrJCancer. 2004;90(3):607-12.
  331. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer Causes of Death in Survivors of Testicular Cancer. JNCI Journal of the National Cancer Institute. 2007;99(7):533-44.
  332. van den Belt-Dusebout A, Nuver J, de Wit R, Gietema JA, Bokkel Huinink WW, Rodrigus PTR, et al. Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. Journal of Clinical Oncology. 2006;24(3):467-75.
  333. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. JClinOncol. 2003;21(8):1513-23.
  334. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. JClinOncol. 2004;22(4):640-7.
  335. Sagstuen H, Aass N, Foss† SD, Dahl O, Klepp O, Wist EA, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. JClinOncol. 2005;23(22):4980-90.
  336. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology. 2007;18(2):241-8.
  337. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der MJ, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. EurJCancer. 2004;40(5):701-6.
  338. Wethal T, Kjekshus J, R›islien J, Ueland T, Andreassen AK, Wergeland R, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv. 2007;1(1):8-16.
  339. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-52.
  340. Wiechno P, Demkow T, Kubiak K, Sadowska M, Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. EurUrol. 2007;52(5):1448-54.
  341. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. BrJCancer. 2005;93(2):200-7.
  342. Gupta SK, Lindemulder EA, Sathyan G. Modeling of circadian testosterone in healthy men and hypogonadal men. The Journal of Clinical Pharmacology. 2000;40(7):731-8.
  343. Bjerner J, Biernat D, Fossa SD, Bjoro T. Reference intervals for serum testosterone, SHBG, LH and FSH in males from the NORIP project. Scandinavian journal of clinical and laboratory investigation. 2009;69(8):873-9 e1-11.
  344. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. EurJEndocrinol. 2004;150(1):65-71.
  345. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036-41.
  346. Laughlin GA, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. Journal of Clinical Endocrinology Metabolism. 2008;93(1):68-75.
  347. Skakkebak NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects: Opinion. Human Reproduction. 2001;16(5):972-8.
  348. Petersen PM, Skakkebaek NE, Rorth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. The Journal of urology. 1999;161(3):822-6.
  349. Carroll PR, Whitmore WF, Jr., Herr HW, Morse MJ, Sogani PC, Bajorunas D, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. The Journal of urology. 1987;137(3):420-3.
  350. DeSantis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. IntJCancer. 1999;83(6):864-5.
  351. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Paternity following treatment for testicular cancer. JNCI Journal of the National Cancer Institute. 2005;97(21):1580-8.
  352. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 Pt 1):287-91; discussion 91-2.
  353. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997;15(1):239-45.
  354. Hansen PV, Trykker H, Svennekjaer IL, Hvolby J. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1990;18(2):117-25.
  355. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. AnnOncol. 1994;5(4):355-8.
  356. Gandini L, Sgro P, Lombardo F, Paoli D, Culasso F, Toselli L, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Human Reproduction. 2006;21(11):2882-9.
  357. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. EurUrol. 2010;58(1):134-41.
  358. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Bjoro T, et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer. 2012;107(11):1833-9.
  359. Reiter WJ, Kratzik C, Brodowicz T, Haitel A, Pokorny A, Zielinski CC, et al. Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology. 1998;52(1):117-9.
  360. Kamischke A, Nieschlag E. Update on medical treatment of ejaculatory disorders. Int J Androl. 2002;25(6):333-44.
  361. Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer: a systematic review. JPsychosomRes. 2001;51(6):735-43.
  362. Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD. Is the sexual function compromised in long-term testicular cancer survivors? EurUrol. 2007;52(5):1438-47.
  363. Tuinman MA, Fleer J, Sleijfer DT, Hoekstra HJ, Hoekstra-Weebers JE. Marital and sexual satisfaction in testicular cancer survivors and their spouses. SupportCare Cancer. 2005;13(7):540-8.
  364. Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. QualLife Res. 2006;15(5):791-800.
  365. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. JClinOncol. 2007;25(6):708-14.
  366. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. AnnOncol. 2002;13(2):222-8.
  367. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. JNCI Journal of the National Cancer Institute. 2009;101(24):1682-95.
  368. Widen SE, Erlandsson SI. Self-reported tinnitus and noise sensitivity among adolescents in Sweden. NoiseHealth. 2004;7(25):29-40.
  369. Shim K, MacKenzie MJ, Winquist E. Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. Drug Saf. 2008;31(5):359-71.
  370. ICRU ICoRUaM. Prescribing, recording and reporting photon beam therapy report 50. Oxford University Press, Oxford, United Kingdom; 1993.
  371. Measurements IICoRUa. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). ICRU Report 62. Oxford University Press, Oxford, United Kingdom 1999.
  372. ICRU ICoRUaM. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU2010. p. pp. 1–106.
  373. Zilli T, Boudreau C, Doucet R, Alizadeh M, Lambert C, van Nguyen T, et al. Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncol. 2011;50(4):555-62.
  374. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56(1):83-8.
  375. Simone CB, 2nd, Kramer K, O'Meara WP, Bekelman JE, Belard A, McDonough J, et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys. 2012;82(1):242-9.
  376. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101-6.
  377. Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012;83(4):e445-52.
  378. Whitelaw GP, Smithwick RH. Some secondary effects of sympathectomy; with particular reference to disturbance of sexual function. N Engl J Med. 1951;245(4):121-30.
  379. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315-20.
  380. Colleselli K, Poisel S, Schachtner W, Bartsch G. Nerve-preserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. J Urol. 1990;144(2 Pt 1):293-7; discussion 7-8.